Shares of HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) rose 7.5% during trading on Tuesday . The company traded as high as $16.44 and last traded at $16.17. Approximately 64,171 shares traded hands during trading, a decline of 40% from the average daily volume of 106,190 shares. The stock had previously closed at $15.04.
Wall Street Analyst Weigh In
Separately, StockNews.com raised shares of HUTCHMED from a "hold" rating to a "buy" rating in a report on Friday, March 21st.
Get Our Latest Analysis on HUTCHMED
HUTCHMED Price Performance
The business's fifty day moving average is $14.90 and its 200-day moving average is $16.37. The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in HCM. Public Employees Retirement System of Ohio bought a new stake in HUTCHMED during the 3rd quarter valued at $35,000. Barclays PLC lifted its stake in HUTCHMED by 1,483.6% in the 4th quarter. Barclays PLC now owns 2,407 shares of the company's stock worth $35,000 after purchasing an additional 2,255 shares in the last quarter. Blue Trust Inc. boosted its stake in HUTCHMED by 99.9% during the fourth quarter. Blue Trust Inc. now owns 7,068 shares of the company's stock valued at $102,000 after buying an additional 3,532 shares during the period. Summit Trail Advisors LLC grew its holdings in shares of HUTCHMED by 14.4% during the fourth quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company's stock worth $189,000 after purchasing an additional 1,647 shares in the last quarter. Finally, OLD Mission Capital LLC purchased a new stake in HUTCHMED in the fourth quarter valued at approximately $230,000. 8.82% of the stock is owned by institutional investors.
HUTCHMED Company Profile
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Featured Articles
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
